Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 * Ovarian, Fallopian Tube or Primary Peritoneal cancer of serous histology * Incurable cancer * Willingness to provide paraffin-embedded tissue blocks of ovarian cancer * Measurable disease * Obtained =\< 14 days prior to registration: Absolute neutrophil count (ANC) \>= 1500 uL * Obtained =\< 14 days prior to registration: Platelet (PLT) \>= 100,000 uL * Obtained =\< 14 days prior to registration: Hemoglobin (Hgb) \>= 9 g/dL * Obtained =\< 14 days prior to registration: Total bilirubin =\< 1.5 x upper limit of normal (ULN) or direct bilirubin =\< ULN * Obtained =\< 14 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN or SGOT (AST) and SGPT (ALT) =\< 5 x ULN is acceptable if liver has tumor involvement * Obtained =\< 14 days prior to registration: Creatinine =\< 1.5 x ULN * Obtained =\< 14 days prior to registration: Fasting serum glucose =\< 1.5 x ULN * Obtained =\< 14 days prior to registration: Total cholesterol =\< 1.5 x ULN * Obtained =\< 14 days prior to registration: Triglycerides =\< 1.5 x ULN * Life expectancy \>= 12 weeks Exclusion Criteria: * Platinum-sensitive disease (exceptions allowed: patient has had a hypersensitivity reaction to platinum or the treating oncologist thinks that further platinum therapy is not in the patient?s best interest) * Morbidities or concurrent major illness (for example, bowel obstruction or a second active malignancy) that, in the opinion of the treating healthcare provider, would make participation in the trial problematic * Leptomeningeal disease or uncontrolled brain metastasis * Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment * NOTE: Patients can have peripheral (sensory) neuropathy * History of hypertriglyceridemia or hypercholesterolemia and currently on medication(s) * Use of St. John?s wort =\< 7 days prior to registration * Unable to discontinue use of a strong CYP3A4 inhibitor